Icon
+91 94997 68112
Login Register

Xtandi - (40 mg; Capsule, Oral)

Enzalutamide Astellas
40 mg; Capsule, Oral
More Than $1000 mn
Less Than 5
More Than 5
More Than 5
Less Than 5
None None
It is used to treat men with a certain type of prostate cancer. This type of prostate cancer has not responded to other treatments to lower the male hormone testosterone and has also spread to other parts of the body.
Yes
******, ***** ****** *** ******* *** *** ***** ** **** **** ** **** ******* '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****) *** **** ************ *********. ** ****** **** **** *** **** ****** ** *** ****. ******* ********* *** ****** **** ***** **** ** **** **** ******* *** **** ************ *********. ********** *** ********* **** ****(*******) & ****** ***** *** ***** ** ********* *** *** *****. ********* ** ********* *** ****** ***** ****** *** *** ******* ******* ** ****. ** ****** **** (*******) & ****** ** ****** **** **** ****** ****. ******* ********** *** ** ******** **** ***** ********* ** ****.
Xtandi Patent 1 Patent 2 Patent 3
******* ******* ******* *******
***** ****** ******* ******* *******
****** ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** **** *, **** ******* ******** ************ ***** *** **** (******** ******)
***** ****** *** \ ** **** *, **** ******* **** ***** *** **** (******** ******)
****** *** \ ** **** *, **** ******* ******** ************ ***** *** **** (******** ******)
  1. *** **, **** : ******, ***** ****** *** ******* ********** ******** ******** ***** *** **** ** **** ******* '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****)
  2. *** *, **** : ******** ***** ******** ***** ******* *** *** ***** ********* ** ******** ***** ** ********.
  3. *** *, **** : ******** ***** * **** ******* ****** ** ****** ***** **** ** **** ******* '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****)
  4. *** **, **** : ******** ***** * **** ******* *********(*****) ** ********* ***** **** ** **** ******* '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****)
  5. *** **, **** : ********** ********* **** ******* *** *** *** ******* ** ****.
  6. *** **, **** : ********** ********* **** ****** *** *** *** ******* ** ****.
  7. *** *, **** : ********** ********* **** ***** ******, ***** *** ***** ** ********* *** *** *****.
  8. *** *, **** : ********** ********* **** *********, ***** *** ***** ** ********* *** *** *****.
  9. *** **, **** : ********* ******* ******** ******** ** *** ****-** ****** **** ******* '*** *** '***.
  10. *** **, **** : ******** **** ******* **** ************ ** ******* '*** *** '***.
  11. *** **, **** : ******** ********* ********** **** ********* *******. ** ****** ** *** * **********.
  12. *** **, **** : **** ******** ********* ********. ** ** *** *********. ** ** ****** **** ***** **** ***** **** ***.

Xtandi - (40 mg, 80 mg Tablet)

Enzalutamide Astellas
40 mg, 80 mg Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
None
No
** **** **, **** ******* **** ****** ** '*** *** '*** *******.
Xtandi Patent 1 Patent 2 Patent 3
****** ******* ******* *** *********
***** ****** ******* *** ********* *** *********
*** ****** ******* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ *** *** **** ******* ********* ******** ***** *** **** (******** ******)
***** ****** ** \ ** *** **, **** ******* **** ***** ***-**** ***********
*** ****** ** \ ** *** **, **** ******* **** ***** ***-**** ***********
  1. *** **, **** : ****-** *** ***** *** ***** ** * *** *******
  2. *** **, **** : ******** **** ****** ** ****** '*** *** '***
  3. *** **, **** : ***** ******** ******** ***** *** ****-** ****** **** ****** '***.
  4. *** *, **** : ******** **** ***** **** ************ ** ****** '***.
  5. *** **, **** : ******** *** ****** ******* ********** ** ******* *****
  6. *** **, **** : *** ******** ******** ** *** ****-** ****** **** ****** '***.
  7. *** **, **** : ******** **** *** **** ************ ** ****** '***.
  8. *** **, **** : ******** *** ***** ******* ********** ** ******* *****.
  9. : ******** *** *** ****** ******* ********** *** *** ****** ****** '*** ************.
  10. *** **, **** : ******** *** *** ****** ******* ********** *** *** ****** ****** '*** ************.
  11. *** **, **** : **** ******** ********* ********. ** ** *** *********. ** ** ****** **** ***** **** ***** **** ***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.